Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10143693 | JANSSEN PHARMS | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
Apr, 2036
(13 years from now) | |
US11324751 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(18 years from now) | |
US11304951 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(18 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Strength (NS) | Aug 30, 2024 |
Market Authorisation Date: 18 May, 2015
Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; Reinitiation of schizophrenia treatment following a missed dose 4-9 months ago; Treatment of schizophrenia by ad...
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
4
United States
3
Australia
3
Japan
2
Morocco
2
Canada
2
European Union
1
Denmark
1
Hong Kong
1
Slovenia
1
Lithuania
1
Hungary
1
Moldova, Republic of
1
Croatia
1
Brazil
1
Portugal
1
Spain
1
Korea, Republic of
1
Poland
1
Taiwan, Province of China
1
RS
1
Ukraine
1
EA
1
New Zealand
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9439906 | JANSSEN PHARMS | Dosing regimen associated with long acting injectable paliperidone esters |
Jan, 2031
(7 years from now) |
Market Authorisation Date: 31 July, 2009
Treatment: Treatment of schizophrenia; Treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; Dosing regimen for the treatment of schizoaffective disorde...
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
5
United States
3
Korea, Republic of
3
European Union
2
Australia
2
China
1
Israel
1
Denmark
1
Hong Kong
1
Slovenia
1
Lithuania
1
Hungary
1
Colombia
1
Croatia
1
Brazil
1
Portugal
1
Guatemala
1
Spain
1
Poland
1
RS
1
Ecuador
1
Nicaragua
1
Ukraine
1
Japan
1
EA
1
Canada
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic